San Diego, January 13, 2026
Travere Therapeutics is experiencing robust performance in the biotechnology sector, with anticipated net product sales reaching approximately $127 million in the fourth quarter of 2025 and a projected total of $410 million for the year. The company is committed to innovation in addressing critical health issues, particularly with its lead product, FILSPARI. With a solid cash position of $323 million, Travere is well-prepared for continued success and the advancement of its clinical developments, including a new drug application targeting Focal Segmental Glomerulosclerosis.
Travere Therapeutics Shows Strong Performance, Poised for Growth
San Diego-based Biotech Company Set for Continued Success in 2026
San Diego, CA – Travere Therapeutics, Inc. (NASDAQ: TVTX) is showcasing a strong performance in the competitive biotechnology sector, particularly with its innovative treatments that are addressing critical health issues. As the company reflects on its preliminary financial results for the fourth quarter and full year of 2025, the progress made highlights the importance of resilience and innovation in today’s economic landscape. The increasing demand for effective therapeutics underscores the entrepreneurial spirit that thrives within California’s robust business environment.
With net product sales anticipated to rise significantly, Travere’s performance serves as a testament to the benefits of a conducive regulatory environment that allows for agility and responsiveness in the healthcare market. As the company navigates the challenges of bringing groundbreaking therapies to market, its commitment to addressing unmet medical needs remains a priority, embodying the spirit of innovation that characterizes many San Diego ventures.
Financial Highlights Demonstrating Growth
Travere Therapeutics anticipates impressive financial figures that reflect its commercial success and strategic focus on key therapeutic areas. The expected U.S. net product sales of approximately $127 million for the fourth quarter of 2025 marks a notable increase from the previous year, while total sales for 2025 are projected to reach around $410 million. This strong performance is underpinned by effective marketing strategies and a decisive commitment to meeting the needs of patients and healthcare providers alike.
As of December 31, 2025, Travere’s financial health is solid with cash, cash equivalents, and marketable securities totaling $323 million. This robust cash position provides a secure foundation for the company’s ongoing operations and research initiatives.
Clinical Developments in Focus
Travere Therapeutics is making significant strides in its clinical developments, particularly with its lead product, FILSPARI® (sparsentan). The drug, aimed at treating IgA Nephropathy (IgAN), has shown remarkable uptake, evidenced by the receipt of 908 new patient start forms in the fourth quarter. Preliminary U.S. net product sales for FILSPARI in this same period are estimated at $103 million, reflecting a substantial 108% year-over-year growth. The partnership with CSL Vifor has further solidified Travere’s presence in international markets, with an additional $40 million milestone payment following FILSPARI’s launch in several European countries.
The upcoming plans for the product pipeline include a supplemental New Drug Application (sNDA) submission for FILSPARI targeting Focal Segmental Glomerulosclerosis (FSGS). If approved, this would mark a historic moment as it would become the first approved medication for this complex kidney disorder.
Upcoming Opportunities for Innovation
In addition to its imminent product launches, Travere is poised to restart clinical trials for its promising therapy, Pegtibatinase (TVT-058), aimed at Classical Homocystinuria (HCU). The company is addressing necessary scale-up improvements within its manufacturing processes and is looking at a timeline to restart enrollment in its pivotal Phase 3 HARMONY Study in 2026. This reflects Travere’s dedication to expanding its portfolio of treatments aimed at conditions that currently have limited therapeutic options.
Looking Ahead to 2026
As Travere Therapeutics sets its sights on 2026, the company is gearing up for a productive year. With plans to launch FILSPARI for FSGS pending regulatory approval and to advance the clinical development of Pegtibatinase, Travere aims to sustain the momentum built in 2025. The landscape for biotechnology in San Diego is undoubtedly enhanced by companies like Travere, which are actively working not just for profit but also for the improvement of patient outcomes in critical areas.
Conclusion: Embracing a Future of Growth
Travere Therapeutics exemplifies the entrepreneurial drive that makes San Diego a hub for innovation in biotechnology. By focusing on groundbreaking therapies and maintaining a strong financial position, the company is well-positioned for future success. Locally-based businesses are an integral part of California’s economic vitality, and Travere’s achievements contribute to a dynamic and resilient landscape. As we support our local entrepreneurs, we look forward to the positive contributions they will continue to make to both our economy and community health.
Frequently Asked Questions (FAQ)
What are the expected net product sales for Travere Therapeutics in the fourth quarter and full year of 2025?
The company anticipates U.S. net product sales of approximately $127 million in the fourth quarter and around $410 million for the full year of 2025.
What is the current cash position of Travere Therapeutics?
As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling approximately $323 million.
What are the key clinical and regulatory developments for Travere Therapeutics?
The company plans to submit a supplemental New Drug Application (sNDA) for FILSPARI in FSGS by the end of the first quarter of 2025 and aims to restart enrollment in the Phase 3 HARMONY Study for pegtibatinase in 2026.
What is the outlook for Travere Therapeutics in 2026?
The company is focused on sustaining the momentum achieved in 2025 and preparing for the successful commercial launch of FILSPARI in FSGS, pending regulatory approval, and advancing its pipeline, including the restart of the pivotal Phase 3 HARMONY Study for pegtibatinase in 2026.
Key Features of Travere Therapeutics’ 2025 Performance
| Feature | Details |
|---|---|
| Fourth Quarter 2025 Net Product Sales | Approximately $127 million |
| Full Year 2025 Net Product Sales | Approximately $410 million |
| Cash Position as of December 31, 2025 | Approximately $323 million in cash, cash equivalents, and marketable securities |
| FILSPARI – IgAN | Received 908 new patient start forms in Q4 2025; $103 million in net product sales in Q4 2025; $40 million milestone payment from CSL Vifor in October 2025 |
| FILSPARI – FSGS | On track to submit sNDA by end of Q1 2025; potential first approved medication for FSGS |
| Pegtibatinase – HCU | Addressing manufacturing scale-up; plans to restart Phase 3 HARMONY Study in 2026 |
| Outlook for 2026 | Focus on sustaining momentum; preparing for FILSPARI launch in FSGS; advancing pipeline, including HARMONY Study restart |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE SAN DIEGO WRITER
The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.
